Proactive Investors - Run By Investors For Investors

Bristol-Myers beats 1Q estimates, guides higher for full-year 2018 on drug approvals

The drug giant reported earnings of $0.94 per share on revenue of US$5.2bn. The consensus estimate from analysts was US$0.85 per share on revenue of US$5.2bn
Bristol raised its earnings guidance for 2018 to US$3.35 to US$3.45

Bristol-Myers Squibb (NYSE:BMY), the pharmaceutical giant, beat Wall Street’s estimates on first-quarter profits, matched on revenues and guided higher on its full-year 2018 earnings forecast.

Bristol-Myers Squibb reported earnings of $0.94 per share on revenue of US$5.2bn. The consensus estimate from analysts came to US$0.85 per share on revenue of US$5.2bn.

Bristol also fared well in the quarter on the drug development front and its results from a clinical trial of Opdivo, its immunotherapy drug as well as another of its cancer-fighting medicines Yervoy cheered investors. When taken in combination, the pair of drugs cut the risk of cancer progression or death in clinical trials by 42% when compared to chemotherapy.

The combination of Opdivo plus Yervoy has been approved in the U.S. for patients with intermediate and poor risk advanced renal cell carcinoma.

READ: Bristol-Myers falls after Citi analyst says Pfizer not interested in buying the drugmaker

“We … obtained FDA approval for Opdivo plus Yervoy in renal cell carcinoma, a disease with high unmet need which represents an important opportunity for the company,” said Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb. “I am confident that strong commercial execution, upcoming Phase 3 readouts across our oncology pipeline and continued strategic use of business development position us well for future growth.”

Bristol’s revenue for the quarter jumped 5% to US$5.19bn, up from US$4.93bn in the same period last year.

Bristol also managed to increase its earnings guidance for 2018 to US$3.35 to US$3.45 per share, up from its previous forecast of US$3.15 to US$3.30 per share and higher than Wall Street’s estimate of US$3.22 per share. 

In pre-market trade, Bristol-Myers Squibb shares edged up slightly to US$52.20.

View full BMY profile View Profile

Bristol-Myers Squibb Co Timeline

Related Articles

LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
Nemaura Medical Inc CEO Dr Faz Chowdhury
November 05 2018
The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use